The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Open accessAbstract
IMPORTANCE: Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain. OBJECTIVE: To determine the rate of progression to diabetes after islet autoantibody seroconversion. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012. MAIN OUTCOMES AND MEASURES: The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies. RESULTS: Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]). CONCLUSIONS AND RELEVANCE: The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The presence of multiple islet autoantibodies (IAA, GADA, IA-2A/IA-2bA, or ZnT8A) is associated with a risk of type 1 diabetes of >90% (408,422,423).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most people with a single autoantibody do not progress to type 1 diabetes, but seroconversion to the presence of two or more serum autoantibodies in children is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years (figure 2A).16”
From Type 1 diabetes (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of the low prevalence of type 1 diabetes (approximately 0.3% in the general population), the positive predictive value of a single islet autoantibody is low (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most individuals without diabetes who have only one autoantibody will not develop type 1 diabetes, as the 10-year risk is about 15% (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a nearcertain predictor of clinical diabetes (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a near-certain predictor of clinical diabetes (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A seminal analysis of four different birth cohorts from the USA, Finland and Germany demonstrated that the presence of a single islet autoantibody is associated with a 13% risk of developing type 1 diabetes over 15 years. In contrast, having two or more antibodies is associated with a 70% risk over 10 years of observation and an 84% risk over 15 years63.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, studies of the offspring of people with diabetes show that young children with multiple autoantibodies develop diabetes during childhood [ 12 ]”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“In children with only one persistent islet autoantibody, the risk of diabetes within 10 years is 15% while two or more islet autoantibodies predict type 1 diabetes in 70% within 10 years (408,409).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Ziegler, A., Hummel, M., Schenker, M., & Bonifacio, E. E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 640
Self-citationGale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Rewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Self-citationQuantification of islet-cell antibodies and prediction of insulin-dependent diabetes
Bonifacio, E. E., Shattock, M., Dean, B. M., Bottazzo, G. F., Bingley, P. J., Gale, E., & Dunger, D. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)90013-u · Cited by 344
Self-citationStratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J. K., Bingley, P. J., Bonifacio, E. E., & Ziegler, A. (2004) · Diabetes · doi:10.2337/diabetes.53.2.384 · Cited by 276
Self-citationOrban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationPREDICTING INSULIN-DEPENDENT DIABETES
Tarn, A., Dean, B., Schwarz, G., Thomas, J. M., Ingram, D., Bottazzo, G. F., & Gale, E. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91601-7 · Cited by 260
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,001
Transitioning to stage 3 type 1 diabetes: when to start insulin
Besser, R. E. J., & Griffin, K. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00238-9 · Cited by 9
Dufrusine, B., Natale, L., Sallese, M., Mozzillo, E., Candia, F. D., Cuccurullo, I., Iafusco, D., Zanfardino, A., Passariello, L., Iannilli, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16002 · Cited by 8
Need for Better Diabetes Treatment: The Therapeutic Potential of NMDA Receptor Antagonists
Welters, A., Lammert, E., Mayatepek, E., & Meißner, T. (2016) · Klinische Pädiatrie · doi:10.1055/s-0042-117831 · Cited by 8
Harrison, L. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00071-5 · Cited by 9
Ninić, A., Bojanin, D., Sopić, M., Mihajlović, M., Munjas, J., Milenković, T., Stefanović, A., Vekić, J., & Spasojević‐Kalimanovska, V. (2020) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2020.2020.0155 · Cited by 8
Sperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 11
Carry, P. M., Waugh, K., Vanderlinden, L. A., Johnson, R. K., Buckner, T., Rewers, M., Steck, A. K., Yang, I. V., Fingerlin, T. E., Kechris, K. J., et al. (2022) · Diabetes · doi:10.2337/db21-1111 · Cited by 8
Self-citationDefinition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2022
Landgraf, R., Heinemann, L., Schleicher, E. D., Gerdes, C., Petersmann, A., Müller‐Wieland, D., Müller, U., Freckmann, G., Thaler, M., Ziegler, A., et al. (2023) · Die Diabetologie · doi:10.1007/s11428-022-00997-z · Cited by 8
Self-citationWhat does the licensing of teplizumab mean for diabetes care?
Quinn, L. M., Swaby, R., Tatović, D., Narendran, P., Besser, R. E. J., & Dayan, C. M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15071 · Cited by 7
Lampousi, A., Carlsson, S., Löfvenborg, J. E., Cabrera-Castro, N., Chirlaque, M., Fagherazzi, G., Franks, P. W., Hampe, C. S., Jakszyn, P. G., Koulman, A., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05948-x · Cited by 8
Chen, D., Kakabadse, D., Fishman, S., Weinstein-Marom, H., Davies, J. E., Boldison, J., Thayer, T. C., Li, W., Gross, G., & Wong, F. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227133 · Cited by 8
Grönholm, J., & Lenardo, M. J. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.11.007 · Cited by 8
Can We Prevent Type 1 Diabetes?
Beauchamp, G., & Haller, M. J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0658-6 · Cited by 8
Islet Autoantibodies and Type 1 Diabetes: Does the Evidence Support Screening?
Calderón, B., & Sacks, D. B. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.212381 · Cited by 8
Chan, C. L., Taki, I., Dong, F., Hoffman, M., Norris, J. M., KLINGENSMITH, G. J., Rewers, M., & Steck, A. K. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0029 · Cited by 8
Self-citationReclassification of asymptomatic beta cell autoimmunity: a critical perspective
Knip, M., Selvenius, J., Siljander, H., & Veijola, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4147-5 · Cited by 8
Self-citationViskari, H., Oikarinen, S., Hoppu, S., Vuorinen, T., Huhtala, H., Toppari, J., Veijola, R., Ilonen, J., Knip, M., & Hyöty, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4410-4 · Cited by 8
Self-citationRationally designed small molecules to prevent type 1 diabetes
Ostrov, D. A., Gottlieb, P. A., & Michels, A. W. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000470 · Cited by 7
Controversies in medicine: redefining the diagnosis of type 1 diabetes
Couper, J., & Harrison, L. C. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50284 · Cited by 8
Wesley, J. D., Pfeiffer, S., Schneider, D., Friedrich, D. A., Perdue, N., Sehested‐Hansen, B., Hagopian, W., & von Herrath, M. G. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1309 · Cited by 8
Fibroma (myxoma) molle in a hamster (Mesocricetus auratus).
West, W. L., Gaillard, E. T., & O'Connor, S. A. (2001) · PubMed · Cited by 8
Wang, B., Hawa, M. I., Rijsdijk, F. V., Fain, P. R., Paschou, S. Α., Boehm, B. O., Steck, A. K., Snieder, H., & Leslie, R. D. (2015) · Diabetologia · doi:10.1007/s00125-015-3664-y · Cited by 8
Self-citationPrecision Diagnostics: Using Islet Autoantibodies to Characterize Heterogeneity in Type 1 DiabetesPreprint
Felton, J. L., REDONDO, M. J., Oram, R. A., Speake, C., Long, S. A., Önengüt-Gümüşcü, S., Rich, S. S., Monaco, G. S. F., Harris-Kawano, A., Perez, D., et al. (2023) · medRxiv · doi:10.1101/2023.04.18.23288756 · Cited by 8
The Role of B Lymphocytes in Type 1 DiabetesPreprint
Smith, M. J., Boldison, J., & Wong, F. S. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041593 · Cited by 10
Factors Governing B Cell Recognition of Autoantigen and Function in Type 1 Diabetes
Bass, L. E., & Bonami, R. H. (2024) · Antibodies · doi:10.3390/antib13020027 · Cited by 9
Faustini, S. E., Quinn, L. M., Hoque, M., Young, S., Bentley, C., Kwok, H. F., Plant, T. D., Litchfield, I. J., Boardman, F., Greenfield, S., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70071 · Cited by 7
Prevalence of Islet Autoantibodies in Adults Without Diabetes
PAULEY, M. E., Simmons, K. M., Dong, F., Yu, L., Steck, A. K., Rasmussen, C. G., Frohnert, B. I., & Rewers, M. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf095 · Cited by 7
Self-citationSwensen, A., Piehowski, P., Chen, J., Chan, X. Y., Kelly, S. S., Petyuk, V., Moore, R., Nasif, L. H., Butterworth, E. A., Atkinson, M. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06417-3 · Cited by 10
Templeman, E. L., Ferrat, L. A., Parikh, H. M., You, L., Triolo, T. M., Steck, A. K., Hagopian, W., Vehik, K., Önengüt-Gümüşcü, S., Gottlieb, P. A., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04225-5 · Cited by 9
Self-citationIs the NOD mouse a good model for type 1 diabetes?
Wong, F. S., Pearson, J. A., & Li, W. (2025) · Diabetologia · doi:10.1007/s00125-025-06579-0 · Cited by 8
Autoimmune reaction against pancreatic beta cells in children and adolescents with simple obesity
Chylińska-Frątczak, A., Pietrzak, I., Michalak, A., Wyka, K., & Szadkowska, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1061671 · Cited by 7
The Etiological Diagnosis of Diabetes: Still a Challenge for the Clinician
Dubois‐Laforgue, D., & Timsit, J. (2023) · Endocrines · doi:10.3390/endocrines4020033 · Cited by 6
HbA1c: an independent risk factor for dysthyroid optic neuropathy
Wang, X., Ye, H., Chen, R., Yang, S., Zhang, T., Xiao, W., & Yang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1251209 · Cited by 7
Giannakopoulos, A., Chrysanthakopoulou, N., Efthymiadou, A., & Chrysis, D. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108667 · Cited by 7
Greenbaum, C. J., Nepom, G. T., Heickman, L. K. W., Wherrett, D. K., DiMeglio, L. A., Herold, K. C., & Krischer, J. P. (2024) · Diabetes · doi:10.2337/dbi24-0020 · Cited by 7
What Have Slow Progressors Taught Us About T1D—Mind the Gap!
Gillespie, K. M., & Long, A. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1219-1 · Cited by 8
Predicting the function of islets after transplantation
Darden, C. M., Farrow, A. E., Rajan, S. K., Lakhani, M., Lawrence, M. C., & Naziruddin, B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00044-7 · Cited by 7
The serum concentration of βCGRP is novel marker for type 1 diabetes
Chen, Y., Lin, Y., Wang, J., Guo, X., Guo, Y., Dong, F., Gao, F., & Liu, Q. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03223 · Cited by 7
Nieto, J., Castillo, B., Astudillo, M., Tosur, M., Balasubramanyam, A., Pietropaolo, M., & REDONDO, M. J. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13238 · Cited by 7
Primary Prevention of CVD with Aspirin: Benefits vs Risks
Weisman (2021) · The Journal of Family Practice · doi:10.12788/jfp.0222 · Cited by 7
How benign autoimmunity becomes detrimental in type 1 diabetes
von Herrath, M., & Bonifacio, E. E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116508118 · Cited by 7
Self-citationMistaken Identity: The Role of Autoantibodies in Endocrine Disease
Nelson, H. A., Joshi, H. R., & Straseski, J. A. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab128 · Cited by 8
Pancreas Islet Cell-Specific Antibody Detection by ELISA
Aelst, S. V., Gillard, P., Weets, I., Dillaerts, D., Billen, J., Mathieu, C., & Bossuyt, X. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab141 · Cited by 7
Banach, M., Harley, I. T. W., Getahun, A., & Cambier, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961209 · Cited by 7
Prevention of Type 1 Diabetes in Children: A Worthy Challenge?
Ingrosso, D. M. F., Quarta, M. T., Quarta, A., & Chiarelli, F. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20115962 · Cited by 7
Mallone, R., Bismuth, É., Thivolet, C., Benhamou, P., Hoffmeister, N., Collet, F., Nicolino, M. P., Reynaud, R., Beltrand, J., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.06.003 · Cited by 8
Following the Fate of the Failing β-Cell: New Insights From First-Phase Insulin Responses
Williams, A. J. K., & Long, A. E. (2013) · Diabetes · doi:10.2337/db13-1314 · Cited by 8
Lindbladh, I., Svärd, A. A., & Lernmark, Å. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00041-5 · Cited by 8
Autoimmunerkrankungen bei Typ 1 Diabetes
Lechleitner, M., Hoppichler, F., & Kaser, S. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0929-x · Cited by 7
Biomarkers in pancreas transplant
Burke, G. W., Chen, L. J., Ciancio, G., & Pugliese, A. (2016) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000333 · Cited by 7
Simmons, K. M., Alkanani, A. K., McDaniel, K. A., Goyne, C., Miao, D., Zhao, Z., Yu, L., & Michels, A. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166213 · Cited by 7
Screening, staging, and naming of presymptomatic type 1 diabetes
Becker, D. J., & Insel, R. A. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12613 · Cited by 10
Probing the Meaning of Persistent Propeptide Release in Type 1 Diabetes
Kahn, S. E., Templin, A. T., Hull, R. L., & Verchere, C. B. (2019) · Diabetes Care · doi:10.2337/dci18-0054 · Cited by 6
Detecting autoreactive B cells in the peripheral blood of people with type 1 diabetes using ELISpot
Powell, W. E., Hanna, S. J., Hocter, C. N., Robinson, E., Lewis, M. D., Dunseath, G. J., Luzio, S. D., Howell, A., Dayan, C. M., & Wong, F. S. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.05.007 · Cited by 7
Tronko, M. D., & Kp, Z. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.6.2019.185403 · Cited by 7
Svärd, A. A., Maziarz, M., Ramelius, A., Lundgren, M., Lernmark, Å., Larsson, H. E., Andersson, C. K., Bennet, R., Jönsson, I., Ask, M., et al. (2020) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2020.100052 · Cited by 7
Tiberti, C., Montuori, M., Trovato, C. M., Panimolle, F., Filardi, T., Valitutti, F., Lenzi, A., Cucchiara, S., & Morano, S. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13054 · Cited by 10
Thrower, S. L., & Bingley, P. J. (2014) · Medicine · doi:10.1016/j.mpmed.2014.09.003 · Cited by 7
The Streetlight Effect—Is There Light at the End of the Tunnel?
Lernmark, Å. (2015) · Diabetes · doi:10.2337/db15-0011 · Cited by 7
Epidemiology of Type 1 Diabetes
Stene, L. C., & Tuomilehto, J. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch3 · Cited by 7
A comparison of current methods to measure antibodies in type 1 diabetes
Infantino, M., Manfredi, M., Garrafa, E., Pancani, S., Lechiara, A., Mobilia, E. M., Grossi, V., Lari, B., Bizzaro, N., & Pesce, G. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0238 · Cited by 6
Harmonising terminology for type 1 diabetes: the EDENT1FI lexicon initiative
Vercauteren, J., Mathieu, C., Gillard, P., Casteels, K., der Schueren, B. V., Overbergh, L., Ziegler, A.-G., Achenbach, P., Winkler, C., Hummel, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00284-0 · Cited by 6
Self-citationAutoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy
Michels, A. W., Gottlieb, P. A., Nelson, B., & Dayan, C. M. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70091 · Cited by 7
Kuusela, S., Koskenniemi, J. J., Valtanen, T., Pokka, T. M.-L., Härkönen, T., Ilonen, J., Lempainen, J., Kyrönniemi, A., Toppari, J., Knip, M., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06573-6 · Cited by 6
Self-citationEckert, A. J., Rosenbauer, J., Kamrath, C., Sindichakis, M., Thimm, A., Holder, M., Weiskorn, J., Lorenz, D. P., Gonzalves, S., Gemulla, G., et al. (2026) · Pediatric Diabetes · doi:10.1155/pedi/6905472 · Cited by 6
Михайловна, Р. Е., Zufarova, I. M., Sorokin, D. Y., Eremina, I. A., Sechko, E. A., Nikankina, L. V., Peterkova, V. A., Bezlepkina, O. B., & Лаптев, Д. Н. (2023) · Diabetes Mellitus · doi:10.14341/dm12955 · Cited by 6
Nutritional Management of Athletes with Type 1 Diabetes: A Narrative Review
Cavallo, M., Fano, M. D., Barana, L., Dozzani, I., Bianchini, E., Pellegrino, M., Cisternino, L., Migliarelli, S., Giulietti, C., Pippi, R., et al. (2024) · Nutrients · doi:10.3390/nu16060907 · Cited by 9
RISING STARS: Evidence for established and emerging forms of β-cell death
Colglazier, K. A., Mukherjee, N., Contreras, C., & Templin, A. T. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0378 · Cited by 6
Dysregulation and therapeutic prospects of regulatory T cells in type 1 diabetes
Khaja, A. S. S., Binsaleh, N. K., Qanash, H., Alshetaiwi, H. S., Ginawi, I., & Saleem, M. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02478-3 · Cited by 8
Characterization of the Human Pancreas Side Population as a Potential Reservoir of Adult Stem Cells
Augstein, P., Loudovaris, T., Bandala‐Sanchez, E., Heinke, P., Naselli, G., Lee, L., Hawthorne, W. J., Góñez, L. J., Neale, A. M., Vaillant, F., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000950 · Cited by 6
Rydzewska, M., Michalak, J., Bossowska, A., Chen, S., Black, S., Powell, M. J., Furmaniak, J., Smith, B. R., & Bossowski, A. T. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0367 · Cited by 6
Sims, E. K., Cuthbertson, D. D., Felton, J. L., Ismail, H. M., Nathan, B. M., Jacobsen, L. M., Paprocki, E. L., Pugliese, A., Palmer, J. P., Atkinson, M. A., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1362 · Cited by 6
The role of endoplasmic reticulum aminopeptidases in type 1 diabetes mellitus
Limanaqi, F., Vicentini, C., Saulle, I., Clerici, M., & Biasin, M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121701 · Cited by 6
Secondary Prevention of Diabetes Type 1 with Oral Calcitriol and Analogs, the PRECAL Study
Papadimitriou, D. T., Dermitzaki, E., Christopoulos, P., Papagianni, M., Kleanthous, K., Marakaki, C., Papadimitriou, A., & Mastorakos, G. P. (2023) · Children · doi:10.3390/children10050862 · Cited by 6
Hebbar, P., Nizam, R., John, S. E., Antony, D., Dashti, M., Channanath, A. M., Shaltout, A., Alkhandari, H., Koistinen, H. A., Tuomilehto, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42255-2 · Cited by 7
Hirvonen, M. K., Lietzén, N., Moulder, R., Bhosale, S. D., Koskenniemi, J. J., Vähä-Mäkilä, M., Nurmio, M., Orešič, M., Ilonen, J., Toppari, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-43039-4 · Cited by 6
Self-citationJohansen, V., Josefsen, K., & Antvorskov, J. (2023) · Nutrients · doi:10.3390/nu15204333 · Cited by 5
Sherman, M. A., Farhadi, P. N., Pak, K. S., Trieu, E. P., Sarkar, K., Targoff, I. N., Neely, M. L., Mammen, A. L., Rider, L. G., & for the Childhood Myositis Heterogeneity Collaborative Study Group (2024) · Arthritis & Rheumatology · doi:10.1002/art.42813 · Cited by 6
Telieps, T., Köhler, M., Treise, I., Foertsch, K., Adler, T., Busch, D. H., de Angelis, M. H., Verschoor, A., Adler, K., Bonifacio, E. E., et al. (2016) · Journal of Diabetes Research · doi:10.1155/2016/4208156 · Cited by 6
Self-citationBagra, B., Mabe, T. L., Tukur, F., & Wei, J. (2020) · Nanotechnology · doi:10.1088/1361-6528/ab8c05 · Cited by 6
Insulin’s other life: an autoantigen in type 1 diabetes
Mannering, S. I., & Bhattacharjee, P. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12442 · Cited by 7
Chuzho, N., Kumar, N., Mishra, N., Tandon, N., Kanga, U., Kaur, G., Singh, P., Mishra, G., Sharma, S., & Mehra, N. K. (2021) · Journal of Diabetes Research · doi:10.1155/2021/4012893 · Cited by 6
Bahendeka, S., Wesonga, R., Piloya, T., & Nyangabyaki, C. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0622-5 · Cited by 6
Identifying the ‘Achilles heel’ of type 1 diabetes
Battaglia, M., Buckner, J. H., Levings, M. K., Richardson, S. J., Wong, F. S., & Tree, T. I. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13570 · Cited by 6
Circulating TFH cells as a marker for early therapeutic intervention in T1D
Bettelli, E., & Campbell, D. (2020) · Nature Immunology · doi:10.1038/s41590-020-0766-6 · Cited by 6
Biomarkers in diabetes mellitus: Advancements, challenges, and future perspectives
Prajapati, A. K., Jha, A. K., & Sheth, D. B. (2024) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2024.012 · Cited by 5
Roberts, A., Tully, A. S., Binkowski, S., Bebbington, K. R., Penno, M. A. S., Anderson, A. J., Craig, M. E., Colman, P. G., Huynh, T., McGorm, K. J., et al. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1479948 · Cited by 5
Type 1 Diabetes and Other Autoimmune Diseases—Epidemiology, Pathophysiology and Screening
Kahaly, G. J., Forst, T. M., Kellerer, M., Lanzinger, S., Rötzer, R. D., Schott, M., & Schumm‐Draeger, P. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70119 · Cited by 7
Hamed, M. S., Nasr, M. S., Mahmoud, H. M., & Yehia, N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.026 · Cited by 5
Fuentes, S., Rodríguez, C. G., Rodríguez-Chacón, C., Toribio, R. G., Hermosín-Escudero, J., Pérez‐Pérez, A., & León‐Justel, A. (2023) · Laboratory Medicine · doi:10.1093/labmed/lmad079 · Cited by 7
Margolis, M. G., Weizman, S., Lazar, L., Yackobovitch‐Gavan, M., Tenenbaum, A., Phillip, M., & Oron, T. (2023) · Diabetic Medicine · doi:10.1111/dme.15250 · Cited by 5
Al‐Mulla, F., Alhomaidah, D. S., Abu‐Farha, M., Hasan, A., Al‐Khairi, I., Nizam, R., Alqabandi, R., Alkandari, H., & Abubaker, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1273476 · Cited by 5
Fletcher, J. D., Olsson, G. E., Zhang, Y. C., & Burkhardt, B. R. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13758 · Cited by 5
Hanna, S. J., Bonami, R. H., Corrie, B., Westley, M., Posgai, A. L., Prak, E. T. L., Breden, F. J., Michels, A. W., Brusko, T. M., Baschal, E. E., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06298-y · Cited by 5
Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review
Mittal, R., McKenna, K., Lemos, J. R. N., Juneja, S., Mittal, M., & Hirani, K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323642 · Cited by 5
Filchtinski, D., Kayser, J., Ettner, V., Holz, S., Kristensen, B. W., Schulte-Pelkum, J., Wilhelm, I., & Fiedler, R. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113885 · Cited by 5
Swaby, R., Narayan, K., Scudder, C. L., Townson, J. K., Oram, R. A., Bell, K. J., Craig, M. E., Dayan, C. M., Aveyard, P. N., & Besser, R. E. J. (2025) · Diabetic Medicine · doi:10.1111/dme.70077 · Cited by 6
Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2019)
Lechleitner, M., Kaser, S., Hofer, S., Hoppichler, F., Roden, M., Weitgasser, R., Fruehwald, L., Ludvik, B. H., Feder, A., Winhofer-Stöckl, Y., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1493-6 · Cited by 5
Imagining a better future for all people with type 1 diabetes mellitus
Korsgren, O., Skyler, J. S., Skog, O., Sundberg, F., Forsander, G., & Ludvigsson, J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0257-8 · Cited by 5
Zhang, M., Wang, X., Wang, R., Shu, J., Zhi, X., Gu, C., Pu, L., Cai, C., Yang, W. Y. L., & Lv, L. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24164 · Cited by 5
Metadata
- Authors
- Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., Bonifacio, E., & Eisenbarth, G. S.
- Affiliations
- TUM Klinikum (DE)
- University of Helsinki (FI)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-19
- Volume
- 309
- Issue
- 23
- Pages
- 2473
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4878912
- OpenAlex
- W2095256598
- Semantic Scholar
- 5a7a8cb24a1d4a727e23b19c717a8328b3ce09d6
- Cited by
- 1,312
- References
- 29
- Citations by year
- 2026: 118 · 2025: 133 · 2024: 103 · 2023: 124 · 2022: 107 · 2021: 127 · 2020: 83 · 2019: 92 · 2018: 92 · 2017: 86 · 2016: 89 · 2015: 83 · 2014: 55 · 2013: 18
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Juvenile Diabetes Research Foundation International (4‐1999‐731, 4‐2001‐435)
- Deutsche Forschungsgemeinschaft (/14-2, /14-1)
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Lastentautien Tutkimussäätiö
- National Institutes of Health (DK32493)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK32493, R01DK032493, U01DK063821)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, seroconversion, multiple autoantibodies, progression to diabetes, insulin autoantibodies, GAD65 antibodies, IA-2 autoantibodies, preclinical diabetes, risk prediction, age at seroconversion, islet transplantation
- MeSH terms
- Adolescent, Autoantibodies, Child, Child, Preschool, Colorado, Diabetes Mellitus, Type 1, Female, Finland, Follow-Up Studies, Genotype, Germany, Glutamate Decarboxylase, Humans, Infant, Insulin, Islets of Langerhans, Male, Prospective Studies, Risk, Disease Progression, Genetic Predisposition to Disease, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
